FT : China vulture funds feast as corporate defaults rise

China vulture funds feast as corporate defaults rise
Debt-market sell-off feeds fast-growing junk bond market worth more than Rmb1.2tn

A new breed of Chinese vulture funds has emerged as rising corporate defaults boost bond yields, creating a fast-growing junk bond market worth more than Rmb1.2tn ($171bn).

The boom has been fuelled by a sell-off in debt markets as issuers ranging from private factories to government investment vehicles run into financial trouble with China’s economy slowing.

However, the high-yield bond bonanza relies heavily on government rescue of troubled borrowers, an expectation that appears increasingly tenuous.

Most vulture funds buy in after issuers show clear signs of distress but before any payments are missed. A small number of investors are bolder, buying bonds that are already in default and thus at a very low price — for instance 10 cents on the dollar — in the hope of an imminent government bailout.

“The value of junk bonds doesn’t depend on credit analysis,” said Larry Hu, an economist at Macquarie Group in Hong Kong. “It depends on the likelihood of a government bailout.”

More than 100 high-yield bond-focused investment groups have emerged since corporate defaults skyrocketed last year, according to East Money Information, a financial information provider. There were fewer than 40 in the previous five years combined.

The rise of vulture investors has been accompanied by a sharp increase in junk bonds as China grapples with its slowest economic growth in 30 years.

A total of 1,434 outstanding corporate bonds yield more than 9 per cent — junk status by local standards, according to East Money Information. That is up from 951 a year ago.

“[The] slowing economy is a boon for junk bonds,” said Shen Xiao, a high-yield bond portfolio manager at Beijing-based Zhongji Investment.

Bond yields have shot up with a record 176 corporate issuers having reneged on debt repayments this year, an increase from 125 in 2018, according to Wind, a financial information provider.

The resulting fire sale of distressed debts by institutional investors, mostly banks and mutual funds, has fed a buying spree by vulture funds snapping up what they consider highly undervalued bonds.

“Bond pricing is getting increasingly irrational as many institutional sellers are offering unusually large discounts to avoid dealing with defaults,” said Jin Yao, a Shanghai-based junk bond portfolio manager.

But more than hopes of a recovery in bond prices, Chinese high-yield investors are banking on the assumption that Beijing will bail out troubled issuers to protect jobs and the economy.

“There are few long-term investors in junk bonds,” said Ivan Chung, an analyst at Moody’s in Hong Kong.

Yet state-led bailouts increasingly are in jeopardy as the central and local governments struggle with shrinking revenue.

Many vulture funds have already suffered heavy losses when an expected rescue package did not materialise.

Wang Yizhong, a Shanghai-based bond portfolio manager, said he lost more than Rmb30m on one-year commercial paper issued by Xiwang Group, a distressed industrial group in eastern Shandong province.

Mr Wang bought the commercial paper after a government-led investment fund pumped Rmb3bn into the troubled corn oil producer. But the money did not resolve Xiwang’s debt problem and local governments were too stretched to provide further help.

“The Chinese government is not as powerful as you think,” said Mr Wang. “They can’t save everyone.”

FT : Unilever: appetite suppressant

Unilever: appetite suppressant
Flagging sales suggest the consumer goods group might need to invest more in the business

High expectations generate resentment later, warn psychologists. Incoming bosses therefore lower the hopes of investors while predecessors can still bear implicit blame. But Alan Jope waived the opportunity for a “reset” of goals when he took over at Unilever in January. That now looks a mistake. On Tuesday, the Anglo-Dutch company said it would miss its full-year revenue growth targets. The share price fell more than 6 per cent.

Not a great start for Mr Jope, a company lifer. But Unilever insists difficult trading conditions are to blame, particularly in south Asia and west Africa. Certainly, it is hard to make headway amid slowdowns such as India’s, where economic growth has halved since the start of 2018.

That is not the case in the US, where Unilever is struggling to combat a resurgent Procter & Gamble. And despite some recent signs of improvement, it has problems in the ice cream market. Unilever is the global leader in the sector but things could get tougher still. Froneri, a private UK business, will become a closer challenger after buying Nestlé’s ice cream brands, including Häagen-Dazs, last week.

Rival Nestlé has been growing faster than Unilever this year. The categories where it competes, such as pet food and coffee, are better performers. That helps explain Nestlé’s premium rating. It trades on a price of 22 times forward earnings, compared with Unilever’s 20 times. Its shares are up 32 per cent this year, nearly twice the increase for Unilever.

Unilever could try to reshape its portfolio, jettisoning slow-growing brands. But M&A is no panacea. Despite buying a number of fashionable “insurgent” brands in recent years, Unilever only generated only about 0.5 percentage points of growth from its acquisitions and disposals in the first half year.

Mr Jope might be better off re-evaluating Unilever’s margin targets, established after the “near death” experience of Kraft Heinz’s failed hostile bid in 2017. Unilever set itself an ambitious cost-cutting programme, adopting some of the “zero-based budgeting” techniques employed by its foiled predator. It believes it can keep up the pace. Cost savings will go on giving it the scope to reinvest in its brands while boosting profitability. But flagging sales suggest it might need to invest more in the business. If they continue to disappoint, it should be prepared to think again.

>>> Fed’s Kaplan (dove, non-voter): trade issues with China are going to be goin

Fed’s Kaplan (dove, non-voter): trade issues with China are going to be going on for a long time - Bloomberg TV interview
- Upward slope to US yield curve suggest monetary policy is in roughly the right place
- No evidence that jobs market is doing anything than getting tighter
- Not seeing weakness in manufacturing spreading
- Potential growth, labor market, financial stability among a variety of factors I will weigh in determining monetary policy decisons
- Reality that technology weighs on pricing power and that is here to stay
- Still willing to tolerate overshoot of 2% inflation target as long is I don't see it as persistent
- Watching corporate bond markets closely looking for excess and potential imbalances; concerned B and BB spreads are so tight
- Negative rates may be example of Central Banks doing too much; repeats Fed would like to avoid negative rates

>>> US Gapping down

Gapping down
In reaction to disappointing earnings/guidance
:

  • UN -6% (lowers outlook), NAV -4.2%, STLD -1.4%

Other news:

  • MEIP -22.3% (announces offering)
  • CLVS -8.4% (files for $250 mln mixed shelf offering)
  • CARS -3% (CEO resigns)
  • APTO -2.9% (announces offering)
  • ROKU -2.6% (CFO to step down)
  • AA -1.6% (to permanently close Point Comfort alumina refinery in Texas)
  • JCAP -1.6% (agrees to internalize external manager)
  • BA -1.4% (confirms it will suspend 737 MAX production in Jan)

Analyst comments:

  • SYNA -5% (downgraded to Sell from Neutral at Rosenblatt)
  • SCPL -3.6% (downgraded to Sell from Buy at Goldman)
  • GRPN -3% (downgraded to Sell from Neutral at Goldman)
  • EAF -2.2% (downgraded to Market Perform from Outperform at BMO Capital Markets)
  • CTL -1.8% (downgraded to Equal-Weight from Overweight at Morgan Stanley)
  • AA -1.6% (downgraded to Market Perform from Outperform at BMO Capital Markets)
  • BAX -1.6% (downgraded to Equal-Weight from Overweight at Morgan Stanley)
  • DHI -1.3% (downgraded to Underperform from Sector Perform at RBC Capital Mkts)
  • ALXN -1.1% (downgraded to Equal-Weight from Overweight at Morgan Stanley)
  • CLR -1.1% (downgraded to Sell from Neutral at Goldman)

>>> US Gapping up

Gapping up
In reaction to strong earnings/guidance
:

  • HEI +2.3% (also increased dividend), LLY +1.2% (raises FY20 guidance)

Other news:

  • TGE +21% (announces agreement for the purchase of its publicly-held class a shares by Blackstone Infrastructure Partners (BIP) for $22.45/share)
  • IMGN +15.7% (reports top-line data from new pivotal single-arm trial, SORAYA, expected in first half of 2021; confirmatory MIRASOL trial for Mirvetuximab on track to start by year-end)
  • BHVN +7.7% (announces 'positive' results from Phase 2/3 clinical trial evaluating the efficacy and tolerability of intranasal vazegepant 5, 10 and 20 mg versus placebo in 1,673 patients for the acute treatment of migraine)
  • PCG +5.3% (amends restructuring support agreement)
  • AGIO +5.1% (receives Breakthrough Therapy Designation for TIBSOVA from the FDA)
  • ALNY +4.9% (announces that the ILLUMINATE-A Phase 3 study of lumasiran for the treatment of primary hyperoxaluria type 1 met its primary efficacy endpoint)
  • PRVL +4.7% (drug candidate granted orphan drug designation)
  • TME +3.6% (announces $400 mln share repurchase program)
  • PCRX +3.1% (announced positive results from its Phase 3 PLAY study of EXPAREL in pediatric patients undergoing spinal or cardiac surgeries)
  • NEX +3% (announces appointment of Kenneth Pucheu as CFO, effective immediately)
  • NOG +2.1% (to commence $0.015/share quarterly cash dividend payment in April 2020)
  • LLY +1.2% {dividend increase)
  • PFE +0.9% (announce FDA approval of XTANDI for the treatment of metastatic castration-sensitive prostate )

Analyst comments:

  • OII +4.8% (upgraded to Buy from Neutral at Goldman)
  • GES +4% (upgraded to Outperform from Market Perform at Cowen)
  • PI +3.4% (upgraded to Buy from Hold at Needham)
  • FCX +1.6% (upgraded to Outperform from Market Perform at BMO Capital Markets)
  • JNJ +1.2% (upgraded to Overweight from Equal-Weight at Morgan Stanley)

FT : JAB to raise up to €3bn in IPO of Douwe Egberts and Peet’s Coffee

JAB to raise up to €3bn in IPO of Douwe Egberts and Peet’s Coffee
Plan to blend businesses would create largest publicly traded pure-play coffee company

Investment company JAB Holdings is combining some of the world’s best-known coffee brands to create a stronger challenger to Nestlé and Starbucks, aiming to raise as much as €3bn from a European listing next year according to people with knowledge of its plans.

JAB will merge Jacobs Douwe Egberts Group (JDE), the world’s second-largest coffee roaster by volume after Nestlé, and Peet’s Coffee, a premium retail US coffee brand, into a single entity to prepare for the listing. If the float takes place, JDE Peet’s will be the largest publicly traded, pure-play coffee company with roughly €7bn in annual sales. It will be run by Peet’s chief executive Casey Keller.

The listing will be one of the largest European initial public offerings slated for 2020. JAB has yet to decide on a venue but is strongly considering the Amsterdam bourse, given the centuries-old Dutch lineage of Douwe Egberts.

The main reason for the listing is to allow an exit for investors that have backed JAB as it went on a deal spree costing more than $50bn across the consumer sector in recent years, said one of the people.

To fuel its expansion, JAB has raised about €12bn since 2012 from university endowments, sovereign wealth funds, and rich families with coffee acquisitions the main focus. US consumer goods group Mondelez will also get the option to sell down its 26 per cent stake in JDE Peet’s, which it received through the merger of its European coffee business with JAB’s Douwe Egberts brands in 2015.

A listing will be a key test for JAB, which was created to manage the wealth of Germany’s billionaire Reimann family, as it seeks to prove that can be a successful operator of businesses and not simply a deal-making machine.

The mooted IPO comes after a difficult year in which JAB has had to rebuild after one of its trio of managing partners, Bart Becht, left after disagreements about strategy. One of its oldest investments, the cosmetics maker Coty Inc, has also stumbled.

The stakes are high for one of JAB’s two remaining managing partners, Olivier Goudet, who came up with the idea of building a global coffee business and pitched the plan to the Reimann family and JAB chairman Peter Harf in 2012, when he was still at Mars. Mr Goudet then joined JAB to carry it out.

JAB is currently in the process of raising additional funds from outside investors, and is on track to collect $8bn by the middle of next year.

JDE Peet’s business is mostly focused on selling packaged roasted coffee beans and capsules under brand names such as Tassimo, Senseo, and L’OR, but a small part of its sales come from preparing hot drinks for customers in Peet’s coffee shops in the US. JDE Peet’s also owns upmarket, speciality US coffee shops such as Intelligentsia Coffee & Tea as well Stumptown Coffee Roasters.

Annual profit has not been disclosed, nor the estimated valuation that JDE Peet’s is seeking from the listing.

Although coffee bean prices paid to farmers remain depressed because of oversupply, business is booming for companies that roast and package coffee.

As a result, the still-fragmented sector has been consolidating with Nestlé seeking to maintain its leadership position, and relative newcomers like JAB and Coca-Cola, which bought the UK’s Costa Coffee last year, striking deals to catch up.

In addition to JDE Peet’s, JAB’s coffee portfolio includes a 67 per cent stake in Keurig Dr Pepper, which sells packaged coffee and capsules for Keurig branded machines.

>>> US Early premarket gappers

Early premarket gappers

  • Gapping up:
    • IMGN +24.2%, TGE +21%, PRVL +16.3%, PCG +5.6%, AGIO +5.1%, LLY +3.1%, LLY +3.1%, NEX +3%, HEI +2.7%, NOG +2.1%, PFE +1%, KL +0.9%, ONCE +0.8%, OFLX +0.7%
  • Gapping down:
    • MEIP -23.1%, CLVS -9.2%, NAV -6.5%, UN -5.9%, ROKU -3.3%, CARS -3%, APTO -2.5%, AA -1.6%, JCAP -1.6%, STLD -1.4%, BA -1.3%